vv International Journal of Clinical Endocrinology and Metabolism 001 Citation: Kochar IS, Ramachandran S, Sethi A (2018) Recombinant Growth hormone response in Indian girls with Turner syndrome. Int J Clin Endocrinol Metab 4(1): 001-003. DOI: http://doi.org/10.17352/ijcem.000029 Clinical Group DOI: http://dx.doi.org/10.17352/ijcem 2640-7582 ISSN: https://dx.doi.org/10.17352/ijcem DOI: Research Article Recombinant Growth hormone response in Indian girls with Turner syndrome Inderpal Singh Kochar 1 *, Smita Ramachandran 2 and Aashish Sethi 3 1 Consultant Pediatric Endocrinology, Indraprashta Apollo Hospital, New Delhi, India 2 Fellow Pediatric endocrinology, Indraprastha Apollo Hospital, New Delhi, India 3 Fellow Pediatric Endocrinology, Indraprastha Apollo Hospital, New Delhi, India Received: 15 October, 2018 Accepted: 27 October, 2018 Published: 29 October, 2018 *Corresponding author: Inderpal Singh Kochar, Consultant Pediatric Endocrinology, Indraprashta Apollo Hospital, New Delhi, India, Tel: 9910240919; E-mail: https://www.peertechz.com Introduction Turner syndrome (TS) is characterized by short statute and ovarian dysgenesis in females with one X chromosome and partial or complete absence of the second X. It has an estimated birth prevalence of 1/2000 to 1/5000 female live births [1]. There is a global growth delay in TS characterized by slight intrauterine growth retardation, delayed growth during infancy and childhood, and lack of a pubertal growth spurt [2]. Typical stigmata include short stature, primary amenor- rhoea, estrogen insufficiency and cardiovascular malforma- tions. Girls with TS universally have short stature (>95%), along- with gonadal failure (>90%) and infertility (99%) [3]. Untreated these girls continue to be short and rarely achieve 150cm of adult height, barring few mosaics [4]. There have been studies that have evaluated the benefits of growth hormone in TS with significant benefit in adult height. This study has been planned to evaluate the presentation and course of Indian girls with Turners syndrome and the response to growth hormone. Methods A retrospective study was planned from 2010 till 2017 in Indraprastha Apollo Hospital, Delhi, in the pediatric and adolescent endocrine clinic, where all the data of girls diagnosed with Turner syndrome treated with recombinant growth hormone, was collected from the patient records. Diagnosis was made on the basis of clinical phenotype, hormonal analysis, and confirmed by karyotypic analysis of a peripheral blood sample. Inclusion criteria Girls with confirmed diagnosis of TS (karyotype), with a height of <–2.5 standard deviation (SD) below the population mean. Patient characteristics 1. At the start of treatment: Patient data were obtained from patient discharge records, Height was measured to the nearest 0.1 cm (Harpenden stadiometer) and weight to the nearest 0.1 kg (Electro W-No- 45). BMI (WT in kg/HT in metre 2 ). Bone age was calculated using RUS score of Tanner Whitehouse 2 method. Thyroid profile, kidney function tests, HbA1c, IGF-1, echocardiography was done at the start. 2. At the end of treatment: Patient parameters recorded were height, weight, BMI, tanner stage, growth velocity (cm/ year). All patients received treatment with recombinant synthetic human GH for at least 12 months, GH was administered by daily subcutaneous injections at the dose 40-50ug/kg/day. The height SD score (HSDS) of patients was calculated based on the Turner’s specific reference data described by Ranke [3,4]. The Z scores were calculated using Microsoft excel using macros. Height, weight, BMI, predicted adult height were all expressed as standard deviation scores. Independent t test and paired t test were used to compare the various pre-treatment and post-treatment data.